1. Hooton TM. Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection. Int J Antimicrob Agents. 2003; 22(Suppl 2):65–72.
Article
2. Fihn SD. Clinical practice. Acute uncomplicated urinary tract infection in women. N Engl J Med. 2003; 349:259–66.
3. Foxman B, Barlow R, D'Arcy H, Gillespie B, Sobel JD. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol. 2000; 10:509–15.
4. Car J. Urinary tract infections in women: diagnosis and management in primary care. BMJ. 2006; 332:94–7.
Article
5. Lee SJ, Lee DS, Choe HS, Shim BS, Kim CS, Kim ME, et al. Antimicrobial resistance in community-acquired urinary tract infections: results from the Korean Antimicrobial Resistance Monitoring System. J Infect Chemother. 2011; 17:440–6.
6. Shin J, Kim J, Wie SH, Cho YK, Lim SK, Shin SY, et al. Fluoroquinolone resistance in uncomplicated acute pyelonephritis: epidemiology and clinical impact. Microb Drug Resist. 2012; 18:169–75.
Article
7. Lee SJ, Lee SD, Cho IR, Sim BS, Lee JG, Kim CS, et al. Antimicrobial susceptibility of uropathogens causing acute uncomplicated cystitis in female outpatients in South Korea: a multicentre study in 2002. Int J Antimicrob Agents. 2004; 24(Suppl 1):S61–4.
Article
8. Wie SH, Choi SM, Lee DG, Kim SY, Kim SI, Yoo JH, et al. Antibiotic sensitivity of the causative organisms and use of antibiotics in women with community-acquired acute pyelonephritis. Korean J Infect Dis. 2002; 34:353–9.
9. Kim SW, Lee JY, Park WJ, Cho YH, Yoon MS. Antibiotic sensitivity to the causative organism of acute simple urinary tract infection for recent 3 years. Korean J Infect Dis. 2000; 32:380–7.
10. Min HJ. Acute pyelonephritis: clinical study and consideration about inpatient therapy. Korean J Med. 1998; 55:232–44.
11. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011; 52:e103–20.
Article
12. Kim ME, Ha US, Cho YH. Prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in female outpatients in South Korea: a multicentre study in 2006. Int J Antimicrob Agents. 2008; 31(Suppl 1):S15–8.
Article
13. Yu Y, Zhou W, Chen Y, Ding Y, Ma Y. Epidemiological and antibiotic resistant study on extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Zhejiang Province. Chin Med J (Engl). 2002; 115:1479–82.
14. Johnson L, Sabel A, Burman WJ, Everhart RM, Rome M, MacKenzie TD, et al. Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med. 2008; 121:876–84.
Article
15. Kahlmeter G. The ECO.SENS Project: a prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens–interim report. J Antimicrob Chemother. 2000; 46(Suppl 1):15–22. ; discussion 63–5.
Article
16. Baudry-Simner PJ, Singh A, Karlowsky JA, Hoban DJ, Zhanel GG. Canadian Antimicrobial Resistance Alliance. Mechanisms of reduced susceptibility to ciprofloxacin in Escherichia coli isolates from Canadian hospitals. Can J Infect Dis Med Microbiol. 2012; 23:e60–4.
17. Hawkey PM, Jones AM. The changing epidemiology of resistance. J Antimicrob Chemother. 2009; 64(Suppl 1):i3–10.
Article
18. Stamey TA, Fair WR, Timothy MM, Millar MA, Mihara G, Lowery YC. Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections. N Engl J Med. 1974; 291:1159–63.
Article
19. Masterton RG, Bochsler JA. High-dosage co-amoxiclav in a single dose versus 7 days of co-trimoxazole as treatment of uncomplicated lower urinary tract infection in women. J Antimicrob Chemother. 1995; 35:129–37.
Article
20. McCarty JM, Richard G, Huck W, Tucker RM, Tosiello RL, Shan M, et al. A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Ciprofloxacin Urinary Tract Infection Group. Am J Med. 1999; 106:292–9.
21. Fang GD, Brennen C, Wagener M, Swanson D, Hilf M, Zadecky L, et al. Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study. Antimicrob Agents Chemother. 1991; 35:1849–55.
Article
22. Lee SE, Choi H, Kim YK. A clinical study of oral fosfomycin (fosmycin) in the treatment of lower urinary tract infection. Korean J Urol. 1984; 25:167–72.
23. Kim KY, Kim CS, Lim DH. The ciprofloxacin resistance pattern of escherichia coli isolated from female patients with community-acquired urinary tract infection in the Jeonnam and Gwangju region for the recent 2-years. Korean J Urol. 2008; 49:540–8.
Article
24. Ryu KH, Kim MK, Jeong YB. A recent study on the antimicrobial sensitivity of the organisms that cause urinary tract Infection. Korean J Urol. 2007; 48:638–45.
Article
25. Lee YW, Chang SK. Clinical efficacy of pivmecillinam (Selexid(R)) in lower urinary tract infections. Korean J Urol. 1983; 24:413–7.
26. Clinical guideline for the diagnosis and treatment of urinary tract infections: asymptomatic bacteriuria, uncomplicated & complicated urinary tract infections, bacterial prostatitis. Infect Chemother. 2011; 43:1–25.